Ani Pharmaceuticals (ANIP) EBITDA (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 16 years of EBITDA data on file, last reported at $38.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 48.46% year-over-year to $38.9 million; the trailing twelve-month figure through Mar 2026 stood at $123.8 million (up 1814.43% YoY), and the FY2025 full-year result was $111.1 million, up 18922.77% from the prior year.
• EBITDA climbed to $38.9 million in Q1 2026, from $34.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $38.9 million in Q1 2026 to a low of -$20.5 million in Q3 2024.
• A 5-year average of $9.5 million and a median of $9.9 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 730.38% in 2022 and jumped 894.13% in 2025, its largest moves.
• Tracing ANIP's EBITDA over 5 years: stood at $1.8 million in 2022, then jumped by 269.56% to $6.7 million in 2023, then sank by 165.09% to -$4.4 million in 2024, then jumped by 894.13% to $34.8 million in 2025, then gained by 11.85% to $38.9 million in 2026.
• Business Quant data shows ANIP's EBITDA at $38.9 million in Q1 2026, $34.8 million in Q4 2025, and $36.2 million in Q3 2025.